top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma approvals, new data, M&A activity, and more - April 5th 2024

$13B acquisition deal + 10 more major updates...👇

Want a list of segmented biopharma companies or access to our online platform? Get more info about our data and how it can help with sales and market intelligence

🎯 → Approvals

🔬 → New data

🤝 → M&A activity

Bristol Myers Squibb

🎯 EC approved Reblozyl® (luspatercept) to include first-line treatment of transfusion-dependent anemia in adults with LR-MDS. 

🎯Received FDA approval for CAR T cell therapy Abecma treating triple-class exposed relapsed or refractory multiple myeloma after two prior lines of therapy. 

Vanda Pharmaceuticals 

🎯FDA approved Fanapt® (iloperidone) acute treatment for bipolar I disorder.


🔬 Received positive recommendation from DSMB and will initiate medium-dose cohort for OCU410 treating geographic atrophy.

Biora Therapeutics 

🔬 Reported interim data for BT-600, advancing NaviCap™ platform development.


🔬 48-Week data reported from the FOREST-HCM trial of Aficamten. 

Candel Therapeutics 

🔬 Interim Ph2 data reported showing increased overall survival of 28.8 months VS 12.5 months in the control group of CAN-2409 in non-metastatic pancreatic cancer. 

CureVac & GSK

🔬 Ph2 interim data reported from the seasonal influenza vaccine development program in collaboration with GSK.

Achilles Therapeutics 

🔬 Reported Ph1/2a interim data from the clonal neoantigen reactive T-Cells in advanced NSCLC and melanoma including first patients dosed with enhanced host conditioning

Johnson & Johnson & Shockwave Medical

🤝 To acquire Shockwave Medical for $13.1B.


Interested in these updates? Get the full update each week → 


April 1-5, 2024

Article History:

RF, DV (04/05/24)


bottom of page